Files and links (2)
Published VersionCC BY-NC-ND V4.0, Open Access
Journal article
Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba
Acta Pharmaceutica Sinica B, Vol.14(1), pp.1-19
2024
Abstract
Bioactive compounds derived from herbal medicinal plants modulate various therapeutic targets and signaling pathways associated with cardiovascular diseases (CVDs), the world’s primary cause of death. Ginkgo biloba, a well-known traditional Chinese medicine with notable cardiovascular actions, has been used as a cardio- and cerebrovascular therapeutic drug and nutraceutical in Asian countries for centuries. Preclinical studies have shown that ginkgolide B, a bioactive component in Ginkgo biloba, can ameliorate atherosclerosis in cultured vascular cells and disease models. Of clinical relevance, several clinical trials are ongoing or being completed to examine the efficacy and safety of ginkgolide B-related drug preparations in the prevention of cerebrovascular diseases, such as ischemia stroke. Here, we present a comprehensive review of the pharmacological activities, pharmacokinetic characteristics, and mechanisms of action of ginkgolide B in atherosclerosis prevention and therapy. We highlight new molecular targets of ginkgolide B, including nicotinamide adenine dinucleotide phosphate oxidases (NADPH oxidase), lectin-like oxidized LDL receptor-1 (LOX-1), sirtuin 1 (SIRT1), platelet-activating factor (PAF), proprotein convertase subtilisin/kexin type 9 (PCSK9) and others. Finally, we provide an overview and discussion of the therapeutic potential of ginkgolide B and highlight the future perspective of developing ginkgolide B as an effective therapeutic agent for treating atherosclerosis.
Details
- Title
- Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba
- Authors
- Weile Ye (Author) - Jinan UniversityJiaojiao Wang (Author) - Jinan UniversityPeter J Little (Author) - University of the Sunshine Coast, Queensland, School of HealthJiami Zou (Author) - Jinan UniversityZhihua Zheng (Author) - Jinan UniversityJing Lu (Author) - Sun Yat-sen UniversityYanjun Yin (Author) - Bengbu Medical CollegeHao Liu (Author) - Bengbu Medical CollegeDongmei Zhang (Author) - Jinan UniversityPeiqing Liu (Author) - Sun Yat-sen UniversitySuowen Xu (Author) - Bengbu Medical CollegeWencai Ye (Author) - Jinan UniversityZhiping Liu (Corresponding Author) - Jinan University
- Publication details
- Acta Pharmaceutica Sinica B, Vol.14(1), pp.1-19
- Publisher
- Elsevier BV
- Date published
- 2024
- DOI
- 10.1016/j.apsb.2023.09.014
- ISSN
- 2211-3843
- Copyright note
- Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
- Grant note
- 82270500, 81870324, 82203304, 82070464, U1401225, U21A20419 / National Natural Science Foundation of China 2019ZX09735002 / National Mega-Project for Innovative Drugs 2017BT01Y036, 2017BT01Y093 / Guangdong Pearl River Talents Program, China 2017B090903004 / National Engineering and Technology Research Center, China
- Organisation Unit
- School of Health; University of the Sunshine Coast, Queensland; School of Health and Behavioural Sciences - Legacy
- Language
- English
- Record Identifier
- 99971198302621
- Output Type
- Journal article
Metrics
1 File views/ downloads
46 Record Views